Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy

Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery

“…The reported incidence of linezolid-related thrombocytopenia varies substantially, ranging from 2.4 to 64.7% [4,5]. This variation could be because of differences among studies with regard to the definition of thrombocytopenia and the characteristics of the study population.…”

“…The major adverse effect associated with linezolid administration is reversible myelosuppression (mostly thrombocytopenia), which may require discontinuation of the drug [2,3]. Several studies have reported that the incidence of thrombocytopenia associated with linezolid therapy is much higher than the 2.4% incidence found in the clinical trials reported by the manufacturer [2,4,5]. However, there few data are available regarding the risk factors for the development of thrombocytopenia during linezolid therapy.…”

Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients

“…Several studies reported that the incidence of linezolid-induced thrombocytopenia was high (7.5-64.7%) [4,[7][8][9][10][11][12][13][14][15]. Risk factors for the development of thrombocytopenia during linezolid therapy include impaired renal function [7,8,10,11,[16][17][18][19][20], chronic liver disease [20,21], the duration of linezolid therapy (≥14 days) [6,7] and respiratory tract infection [7].…”

Population Pharmacokinetic and Pharmacodynamic Analysis of Linezolid and a Hematologic Side Effect, Thrombocytopenia, in Japanese Patients

“…The incidence of LZD-induced thrombocytopenia varies from 2.4 to 64.7% (3,6,14,22,28,30,34), and little is known about the mechanism responsible. Recent studies, however, have shown the incidence of LZD-induced thrombocytopenia to be significantly higher in patients treated long term (Ͼ14 days) (16) or with insufficient renal function (22,25,34), and it is lower in patients coadministered rifampin, which significantly reduced the area under the curve (AUC) of LZD (34,12).…”